Literature DB >> 33431989

Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells.

Barbara S Paugh1, Lajos Baranyi1, Andre Roy1, Hua-Jun He2, Lindsay Harris2, Kenneth D Cole2, Moria Artlip1, Caroline Raimund1, Patricia S Langan1, Srikanta Jana1, Rimas J Orentas1, Sheng Lin-Gibson3, Winfried Krueger4, Boro Dropulić5.   

Abstract

Lentiviral vectors (LV) have emerged as a robust technology for therapeutic gene delivery into human cells as advanced medicinal products. As these products are increasingly commercialized, there are concomitant demands for their characterization to ensure safety, efficacy and consistency. Standards are essential for accurately measuring parameters for such product characterization. A critical parameter is the vector copy number (VCN) which measures the genetic dose of a transgene present in gene-modified cells. Here we describe a set of clonal Jurkat cell lines with defined copy numbers of a reference lentiviral vector integrated into their genomes. Genomic DNA was characterized for copy number, genomic integrity and integration coordinates and showed uniform performance across independent quantitative PCR assays. Stability studies during continuous long-term culture demonstrated sustained renewability of the reference standard source material. DNA from the Jurkat VCN standards would be useful for control of quantitative PCR assays for VCN determination in LV gene-modified cellular products and clinical samples.

Entities:  

Year:  2021        PMID: 33431989      PMCID: PMC7801692          DOI: 10.1038/s41598-020-79698-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  19 in total

1.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.

Authors:  Giorgia Santilli; Elena Almarza; Christian Brendel; Uimook Choi; Chiara Beilin; Michael P Blundell; Sneha Haria; Kathryn L Parsley; Christine Kinnon; Harry L Malech; Juan A Bueren; Manuel Grez; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

2.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.

Authors:  Stephen A Bustin; Vladimir Benes; Jeremy A Garson; Jan Hellemans; Jim Huggett; Mikael Kubista; Reinhold Mueller; Tania Nolan; Michael W Pfaffl; Gregory L Shipley; Jo Vandesompele; Carl T Wittwer
Journal:  Clin Chem       Date:  2009-02-26       Impact factor: 8.327

3.  Reference Standards for Gene and Cell Therapy Products.

Authors:  Boro Dropulić
Journal:  Mol Ther       Date:  2017-05-11       Impact factor: 11.454

4.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

5.  Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.

Authors:  Ewelina Mamcarz; Sheng Zhou; Timothy Lockey; Hossam Abdelsamed; Shane J Cross; Guolian Kang; Zhijun Ma; Jose Condori; Jola Dowdy; Brandon Triplett; Chen Li; Gabriela Maron; Juan C Aldave Becerra; Joseph A Church; Elif Dokmeci; James T Love; Ana C da Matta Ain; Hedi van der Watt; Xing Tang; William Janssen; Byoung Y Ryu; Suk See De Ravin; Mitchell J Weiss; Benjamin Youngblood; Janel R Long-Boyle; Stephen Gottschalk; Michael M Meagher; Harry L Malech; Jennifer M Puck; Morton J Cowan; Brian P Sorrentino
Journal:  N Engl J Med       Date:  2019-04-18       Impact factor: 91.245

6.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Alessandro Aiuti; Federica Cattaneo; Stefania Galimberti; Ulrike Benninghoff; Barbara Cassani; Luciano Callegaro; Samantha Scaramuzza; Grazia Andolfi; Massimiliano Mirolo; Immacolata Brigida; Antonella Tabucchi; Filippo Carlucci; Martha Eibl; Memet Aker; Shimon Slavin; Hamoud Al-Mousa; Abdulaziz Al Ghonaium; Alina Ferster; Andrea Duppenthaler; Luigi Notarangelo; Uwe Wintergerst; Rebecca H Buckley; Marco Bregni; Sarah Marktel; Maria Grazia Valsecchi; Paolo Rossi; Fabio Ciceri; Roberto Miniero; Claudio Bordignon; Maria-Grazia Roncarolo
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

Review 7.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

8.  Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.

Authors:  Florian Eichler; Christine Duncan; Patricia L Musolino; Paul J Orchard; Satiro De Oliveira; Adrian J Thrasher; Myriam Armant; Colleen Dansereau; Troy C Lund; Weston P Miller; Gerald V Raymond; Raman Sankar; Ami J Shah; Caroline Sevin; H Bobby Gaspar; Paul Gissen; Hernan Amartino; Drago Bratkovic; Nicholas J C Smith; Asif M Paker; Esther Shamir; Tara O'Meara; David Davidson; Patrick Aubourg; David A Williams
Journal:  N Engl J Med       Date:  2017-10-04       Impact factor: 91.245

9.  Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.

Authors:  Denise A Carbonaro; Lin Zhang; Xiangyang Jin; Claudia Montiel-Equihua; Sabine Geiger; Marlene Carmo; Aaron Cooper; Lynette Fairbanks; Michael L Kaufman; Neil J Sebire; Roger P Hollis; Michael P Blundell; Shantha Senadheera; Pei-Yu Fu; Arineh Sahaghian; Rebecca Y Chan; Xiaoyan Wang; Kenneth Cornetta; Adrian J Thrasher; Donald B Kohn; H Bobby Gaspar
Journal:  Mol Ther       Date:  2013-11-20       Impact factor: 11.454

Review 10.  A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.

Authors:  Michael White; Roger Whittaker; Carolina Gándara; Elizabeth A Stoll
Journal:  Hum Gene Ther Methods       Date:  2017-08       Impact factor: 2.396

View more
  2 in total

1.  Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products.

Authors:  Daniela Nascimento Silva; Michael Chrobok; Giulia Rovesti; Katie Healy; Arnika Kathleen Wagner; Panagiota Maravelia; Francesca Gatto; Massimiliano Mazza; Lucia Mazzotti; Volker Lohmann; Margaret Sällberg Chen; Matti Sällberg; Marcus Buggert; Anna Pasetto
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

2.  Applicability of Control Materials To Support Gene Promoter Characterization and Expression in Engineered Cells Using Digital PCR.

Authors:  Ana Fernandez-Gonzalez; Simon Cowen; Juhyun Kim; Carole A Foy; Jose Jimenez; Jim F Huggett; Alexandra S Whale
Journal:  Anal Chem       Date:  2022-03-31       Impact factor: 6.986

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.